Author

C. Morrissey

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 8 Biophysics· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 9 Approach:experimental assay· 8 Research Focus:cell type annotation· 5 Research Focus:cancer & tumor microenvironment· 3 Research Focus:differential expression· 3 Assay:proteomics· 3 Assay:bulk RNA-seq· 2 Assay:imaging· 2

Frequent Co-Authors

E. COREY· 6 shared P. S. Nelson· 4 shared L. Ellis· 3 shared H. M. Nguyen· 2 shared I. Coleman· 2 shared J. E. Berchuck· 2 shared L. M. Cook· 2 shared M. E. Cox· 2 shared

Activity by Year

2018-2024 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

6 shared papersCancer Biology

E. COREY

Mutual co-authors in cluster

Author profile →

9 papers

Recent·Most cited

Imaging and quantification of prostate cancer-associated bone by polarization-sensitive optical coherence tomography

C. Zhou, N. JUNG, S. XU, F. E. GUERSETTI, X. Lu, Q. WANG, D. LIANG, C. MORRISSEY, E. COREY, L. TRUE, R. Wang, S. Tang, M. E. Cox

This study uses PS-OCT to differentiate bone tissue types in prostate cancer metastases by analyzing collagen organization and quantifying structural features.

bioRxiv · Feb 21, 2024 · PreprintBiophysics

ONECUT2 Activates Diverse Resistance Drivers of Androgen Receptor-Independent Heterogeneity in Prostate Cancer

C. Qian, Q. Yang, M. Rotinen, R. Huang, h. Kim, B. Gallent, Y. Yan, R. M. Cadaneanu, B. Zhang, S. Kaochar, S. J. Freedland, E. M. Posadas, L. Ellis, D. Di Vizio, C. Morrissey, , M. R. Freeman

This study identifies ONECUT2 as a master transcription factor that drives resistance in prostate cancer through multiple mechanisms, including activation of neuroendocrine and adenocarcinoma variants, and shows that its inhibition can suppress treatment-resistant lineage plasticity.

bioRxiv · Sep 28, 2023 · PreprintCancer Biology

Sclerotic prostate cancer bone metastasis: woven bone lesions with a twist.

F. Y. Eltit, Q. Wang, N. Jung, S. Munshan, D. Xie, S. Xu, B. Mojtahedzadeh, D. Liu, E. Corey, L. E. True, C. Morrissey, R. Wang, M. E. Cox

This study characterizes the bone structure of prostate cancer bone metastases using multiple techniques and identifies four phenotypes, including osteosclerotic lesions with abnormal woven bone-like features.

bioRxiv · Sep 11, 2023 · PreprintCancer Biology

GD2 and its biosynthetic enzyme GD3 synthase promote tumorigenesis in prostate cancer by regulating cancer stem cell behavior

A. M. Bhat, B. C. Mohapatra, H. Luan, I. Mushtaq, S. Chakraborty, S. Kumar, W. Wu, B. Nolan, S. Dutta, M. D. Stock, M. Schott, J. L. Meza, S. M. Lele, M.-F. Lin, L. M. Cook, , H. Band

This study shows GD2 and its biosynthetic enzyme GD3S promote prostate cancer tumorigenesis by maintaining cancer stem cells and EMT markers.

bioRxiv · Mar 18, 2023Cancer Biology

Androgen-mediated TGFβ expression suppresses anti-tumor neutrophil response in bone metastatic prostate cancer

M. Alsamraae, D. Costanzo-Garvey, B. A. Teply, S. Boyle, G. Sommerville, Z. Herbert, C. Morrissey, A. J. Dafferner, M. Y. Abdalla, R. W. Fallet, T. Kielian, H. Jensen-Smith, E. I. deOliveira, K. Chen, I. A. Bettencourt, , L. M. Cook

This study identifies androgen-mediated TGFβ expression as a mechanism suppressing anti-tumor neutrophil response in bone metastatic prostate cancer and shows that combining ADT with TGFβ receptor inhibition restores neutrophil cytotoxicity.

bioRxiv · Dec 30, 2022 · PreprintCancer Biology

Nucleosome patterns in circulating tumor DNA reveal transcriptional regulation of advanced prostate cancer phenotypes

N. De Sarkar, R. D. Patton, A.-L. Doebley, B. Hanratty, A. J. Kreitzman, J. F. Sarthy, M. Ko, M. Adil, S. Brahma, M. P. Meers, D. H. Janssens, L. S. Ang, I. Coleman, A. Bose, R. F. Dumpit, , G. Ha

This paper identifies nucleosome patterns in ctDNA that distinguish advanced prostate cancer phenotypes, achieving high accuracy in classification using a prediction model.

bioRxiv · Jun 21, 2022Cancer Biology

Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer

S. C. Baca, D. Y. Takeda, J.-H. Seo, J. Hwang, S. Y. Ku, R. Arafeh, T. Arnoff, S. Agarwal, C. Bell, E. O'Connor, X. Qiu, S. Abu Alaiwi, R. I. Corona, M. A. S. Fonseca, C. Giambartolomei, , M. L. Freedman

The paper identifies FOXA1 reprogramming in NEPC and shows its role in maintaining NE lineage features through epigenomic profiling.

bioRxiv · Oct 23, 2020Cancer Biology

Targeting RET Kinase in Neuroendocrine Prostate Cancer

H. VanDeusen, J. R. Ramroop, K. L. Morel, A. V. Sheahan, Z. Sychev, N. A. Lau, L. C. Cheng, V. Tan, Z. Li, A. Petersen, J. K. Lee, J. Wook Park, R. Yang, I. Coleman, O. N. Witte, , J. M. Drake

The paper identifies RET kinase as a targetable driver in neuroendocrine prostate cancer (NEPC) through phosphoproteomics and pharmacological inhibition studies, showing reduced tumor growth in models.

bioRxiv · Apr 29, 2019Cancer Biology

ALDH1-positive intratumoral stromal cells indicate epithelial differentiation and good prognosis in prostate cancer

P. Nastaly, M. Filipska, C. Morrissey, E. Eltze, A. Semjonow, B. Brandt, K. Pantel, N. Bednarz-Knoll

The paper examines ALDH1 expression in prostate cancer stromal cells, finding it correlates with better prognosis and more differentiated epithelial phenotypes.

bioRxiv · Mar 5, 2018Cancer Biology